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Letters to the Editorthat ligation of a single pulmonary
vein, either superior or inferior, may
be accompanied by dilation of collat-
eral veins to the azygous system,which
may be compatiblewith life.4 This area
requires further study, and conclusions
should not be based a single case.
In surgical emergencies, a transected
main pulmonary artery does not pre-
clude abrupt abortion of the intended
surgical procedure. However, this
should be used as a last resort. In elec-
tive cancer cases, a thorough inspection
of all structures including artery, veins,
and bronchus should be undertaken to
ensure resectability before transection
of any individual major structure.
Raja M. Flores, MD
Chief of Thoracic Surgery
Mount Sinai School of Medicine
New York, NY
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FENESTRATE
To the Editor:
In their recent article, Salazar and
colleagues1 have rightly addressed
a pertinent topic. We agree that under
usual circumstances a fenestration at
the time of a total cavopulmonary
connection should be avoided. Be-
tween June 2000 and June 2006, a total
of 132 consecutive patients were
treated at our institution without any
fenestrations. At the time of total cav-
opulmonary connection, 93 patients
(70%) were younger than 48 months.
We continue to complete at a young598 The Journal of Thoracic and Cage and to avoid fenestrations. We
have since opted for fenestration in
only 2 patients, both of whom under-
went single-lung palliation.
Salazar and colleagues1 state that
they opted for fenestration only in
‘‘highly selected patients.’’ They men-
tion patients with elevated pulmonary
vascular resistance or transpulmonary
gradient, significant atrioventricular re-
gurgitation, and single-lung physiol-
ogy. We would appreciate further
guidance on their selection criteria, be-
cause we would like to know their cut-
off for elevated pulmonary vascular
resistance and why they deem patients
with atrioventricular regurgitation to
be candidates for fenestration. In addi-
tion, why should any intracardiac anat-
omynot be amenable to an extracardiac
completion? In our view, the extracar-
diac completion does in fact help to
overcome many complex morphologic
obstacles and helps make it quite easy
to reroute central venous blood flow
to the pulmonary vascular bed.
Salazar and colleagues1 might also
elucidate their experience with fenes-
tration patency. Ruiz and colleagues2
have published an intriguing concept
in which the lower atrial orifice toward
the divided inferior vena cava is su-
tured in an end-to-side fashion to the
leftward aspect of thepunched conduit.
Christian Schreiber, MD, PhD
J€urgen H€orer, MD, PhD
R€udiger Lange, MD, PhD
Department of Cardiovascular
Surgery
German Heart Center Munich at the
Technical University
Munich, Germany
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HYPERLACTATEMIA AFTER
SURGICAL REPAIR OF
SECUNDUM ATRIAL SEPTAL
DEFECT IN CHILDREN: WHAT
IS THE PROBLEM?
To the Editor:
We read with great interest the arti-
cle by Abraham and colleagues.1 They
report their results of a retrospective
study on the intraoperative risk factors
for early postoperative hyperlactate-
mia in patients undergoing atrial sep-
tal defect repair. Multivariate logistic
regression analysis showed that lower
cardiopulmonary bypass (CPB) flow
rate is an independent risk factor for
early postoperative hyperlactatemia
in children after atrial septal defect re-
pair. It has instructive significance for
the perfusionist to maintain higher
mixed venous saturations and use va-
sodilators during CPB to improve
overall tissue perfusion.
The study includes 68 patients with
atrial septal defect, Risk Adjustment
for Congenital Heart Surgery category
I, who had good cardiac output in the
postoperative period. This effectively
avoids the influence of confounding
factors on blood lactate, such as the
CPB temperature, hemodilution, du-
ration of CPB, cardiac function, drugs
used perioperatively, liver and kidney
function, and so forth. The design is
a benefit for the study of the correla-
tion simply between intraoperative
factors and postoperative hyperlacta-
temia. However, several other factors
that influence the blood lactate should
be considered.
The subjects have atrial septal de-
fect and are aged less than 21 years
(range, 5–201 months). The age span
is comparatively large because there
is a big difference in the CPB prime
and management between those aged
5 months and those aged 201 months.
Generally, children aged less than 1
year would be primed with banked
red blood cells and have compara-
tively more banked blood periopera-
tively. Banked blood itself, which
Letters to the Editorindicates lactate acidosis, will affect
the blood lactate concentration, espe-
cially in very little infants.2 This study
has not analyzed the use of banked
blood in 2 groups statistically. There-
fore, is it more appropriate to limit
the inclusion objects to a more narrow
age span?
Second, crystal solutions would be
used in the extracorporeal circulation.
The crystal solutions in use now in-
clude Ringer’s lactate and Ringer’s ac-
etate. Lactate has 2 isoforms: L-lactate
and D-lactate. L-lactate is the products
of anaerobic glycolysis in humans and
has been used as a marker of cellular
hypoxia and tissue malperfusion.3 It
would be converted to sodium bicar-
bonate by tricarboxylic acid cycle.
However, D-lactate is mostly exoge-
nous from Ringer’s lactate solution.
Its clearance is much slower than L-
lactate, mainly depending on the liver
function.3 Massive exogenous D-lac-
tate Ringer’s solution infusion would
cause iatrogenic hyperlactacidemia
in those infants with immature liver
function. This phenomenon would
not occur when Ringer’s acetate is
used in CPB. However, this study has
not mentioned the kinds and dosage
of the crystal solution.
Ronghua Zhou, MD
Jin Liu, MD, PhD
Department of Anesthesiology
West China Hospital
Sichuan University
Chengdu, Sichuan, ChinaReferences
1. Abraham BP, Prodhan P, Jaquiss RDB, et al. Car-
diopulmonary bypass flow rate: a risk factor for hy-
perlactatemia after surgical repair of secundum
atrial septal defect in children. J Thorac Cardiovasc
Surg. 2010;139:170-3.
2. Hamamoto M, Uemura H, Imanaka H, Yagihara T.
Relevance of the measurement of the concentration
of lactate in the serum subsequent to the Fontan
procedure in small children. Cardiol Young. 2006;
16:275-80.
3. Nakatani T. Overview of the effects of Ringer’s ac-
etate solution and a new concept: renal ketogenesis
during hepatic inflow occlusion.Methods Find Exp
Clin Pharmacol. 2001;23:519-28.
doi:10.1016/j.jtcvs.2010.09.059The JournalCOMMENT ON EDITORIAL BY
LAPEYRE AND COLLEAGUES
To the Editor:
The editorial by Lapeyre and
colleagues,1 ‘‘Prosthetic heart valves:
Difficult to make something simple,’’
emphasizes the need for more dura-
ble tissue valves for patients younger
than 65 years, especially juveniles
and young adults in emerging coun-
tries. To address that need, our group
has worked on the concept of a non-
immunogenic autologous tissue valve
for the last 25 years. The initial clin-
ical application was a stent-mounted
valve made in the operating room at
the time of valve replacement.2
More recently, a totally stentless
aortic valve made with disposable in-
struments at the time of valve re-
placement has been developed and
used clinically.3 Follow-up of the first
11 patients implanted with the stent-
less autologous pericardial valve in
a prospective pilot study from Febru-
ary 2003 to May 2005 at the Hare-
field Hospital by Dreyfus can be
seen, before publication, on the
webcast of the 2010 American Asso-
ciation for Thoracic Surgery annual
meeting in Toronto.4 The first patient
in the series was a 42-year-old man
with a heavily calcified bicuspid aor-
tic valve, a gradient of 131 mm Hg,
and an ascending aortic aneurysm.
He has normal valve function with
no evidence of calcification 7.2 years
post-aortic valve reconstruction. The
last patient in the series was a 22-
year-old woman with congenital aor-
tic stenosis and a calcified bicuspid
aortic valve with a gradient of 71
mm Hg. She has normal valve func-
tion with no evidence of calcification
5 years after aortic outflow enlarge-
ment and aortic valve reconstruction.
These results suggest that lightly
tanned autologous pericardium may
be a suitable biomaterial for fabricat-
ing a more durable tissue heart valve
for younger patients. The use of
autologous tissue and disposable
instruments for the valve reconstruc-of Thoracic and Cardiovascular Surgetion has the potential for being
a cost-effective solution to the need
for a tissue heart valve in emerging
countries.
It is largely forgotten that the first
tissue heart valves weremade of autol-
ogous tissue, by Ake Senning in the
early 1960s. He did freehand recon-
struction of aortic valves with the
patient’s own fascia lata. Senning ex-
plained presciently why he used autol-
ogous tissue: ‘‘Having worked with
organ transplantation, I felt the allo-
grafts or homografts would be slowly
destroyed by immunologic factors. In
the same year, I began replacing the
aortic valve with autogenous fascia
lata, which was taken sterile at the
time of operation, eliminating the
problems of sterilization, preserva-
tion, immunologic reactions, and
thromboembolism.’’5 He used un-
treated autologous fascia lata, and al-
though 18 of 90 patients survived 12
to 20 years with their reconstructed
aortic valves, 13 with ‘‘no or minimal
dysfunction,’’ most of the valves be-
came insufficient because of thicken-
ing and shrinkage of the tissue.
Others, notably Bj€ork6 and Edwards,7
confirmed poor results with untreated
fascia lata and pericardium, and the
use of autologous tissue fell out of
favor. On revisiting the concept, we
discovered serendipitously that a brief
immersion of autologous pericardium
in dilute buffered glutaraldehyde so-
lution, light tanning,2 eliminated the
thickening and shrinkage that had
been observed by Senning, Bjork,
and Edwards. The tissue had a healthy,
pristine appearance after valve im-
plantation for 5 months in juvenile
sheep, a known severe test for calcific
degeneration. Love8 summarized the
early history of autologous tissue
heart valves in a monograph on the
subject.
The valve industry has shown little
interest in an autologous tissue heart
valve that might prove to be more du-
rable and cost a fraction of currently
available bioprostheses.ry c Volume 141, Number 2 599
